CAP-1002 – VJRegenMed https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Thu, 26 Aug 2021 17:53:54 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png CAP-1002 – VJRegenMed https://mirror.vjregenmed.com 32 32 Cardiosphere-derived cells in myocardial regeneration https://mirror.vjregenmed.com/video/ucyqsv5npcu-cardiosphere-derived-cells-in-myocardial-regeneration/ Fri, 13 Aug 2021 12:05:07 +0000 http://13.40.107.223/video/ucyqsv5npcu-cardiosphere-derived-cells-in-myocardial-regeneration/ Linda Marban, PhD, Capricor Therapeutics, Beverly Hills, CA, introduces CAP-1002, an allogeneic cardiosphere-derived cell (CDC) therapy that promotes the regeneration of cardiac muscle by stimulating the release of exosomes, thus inducing endogenous repair mechanisms, a reduction in inflammation and ultimately, muscle tissue generation. Clinical trial data indicates that CAP-1002 therapy can result in significant improvements in cardiac and skeletal muscle in patients with Duchenne muscular dystrophy (DMD). CDC-derived extracellular vesicles (EVs) are also being investigated as a therapeutic given their tropism to cardiac and skeletal muscle and ease of storage and delivery. This interview took place during the American Society for Cell & Gene Therapy 24th Annual Meeting 2021.

]]>